Boston Scientific cancels $230M stent deal after regulators erect barriers to acquisition
Boston Scientific has canceled a planned $230 million acquisition of a majority stake in M.I.Tech, a Korean manufacturer of non-vascular stents.
Boston Scientific has canceled a planned $230 million acquisition of a majority stake in M.I.Tech, a Korean manufacturer of non-vascular stents.
Based on recent headline ratings, 83% of this readership currently trusts the local media, which has an average score of 75% regionally and is currently trending negative.